Header Logo

Connection

JIUN-KAE JACK LEE to Biomarkers, Tumor

Back to Details
This is a "connection" page, showing publications JIUN-KAE JACK LEE has written about Biomarkers, Tumor.
JIUN-KAE JACK LEE
Connection Strength
0.851
Biomarkers, Tumor
  1. Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine. Clin Trials. 2008; 5(3):181-93.
    View in: PubMed
    Score: 0.078
  2. Long-term impact of smoking on lung epithelial proliferation in current and former smokers. J Natl Cancer Inst. 2001 Jul 18; 93(14):1081-8.
    View in: PubMed
    Score: 0.050
  3. Design considerations for efficient prostate cancer chemoprevention trials. Urology. 2001 Apr; 57(4 Suppl 1):205-12.
    View in: PubMed
    Score: 0.049
  4. Expression of heterogeneous nuclear ribonucleoprotein A2/B1 in bronchial epithelium of chronic smokers. Clin Cancer Res. 1998 Jul; 4(7):1631-40.
    View in: PubMed
    Score: 0.041
  5. Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval. J Natl Cancer Inst. 2015 Nov; 107(11).
    View in: PubMed
    Score: 0.033
  6. Membrane carbonic anhydrase IX expression and relapse risk in resected stage I-II non-small-cell lung cancer. J Thorac Oncol. 2014 May; 9(5):675-84.
    View in: PubMed
    Score: 0.030
  7. Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial. Clin Cancer Res. 2013 Dec 15; 19(24):6967-75.
    View in: PubMed
    Score: 0.029
  8. EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma. Clin Cancer Res. 2013 Dec 01; 19(23):6556-65.
    View in: PubMed
    Score: 0.029
  9. Prognostic value of the trichorhinophalangeal syndrome-1 (TRPS-1), a GATA family transcription factor, in early-stage breast cancer. Ann Oncol. 2013 Oct; 24(10):2534-2542.
    View in: PubMed
    Score: 0.028
  10. Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial. J Thorac Oncol. 2013 May; 8(5):658-61.
    View in: PubMed
    Score: 0.028
  11. Feasibility of image-guided transthoracic core-needle biopsy in the BATTLE lung trial. J Thorac Oncol. 2013 Apr; 8(4):436-42.
    View in: PubMed
    Score: 0.028
  12. Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial. J Thorac Oncol. 2012 Nov; 7(11):1645-52.
    View in: PubMed
    Score: 0.027
  13. Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. J Thorac Oncol. 2011 Dec; 6(12):2104-11.
    View in: PubMed
    Score: 0.026
  14. The BATTLE to personalize lung cancer prevention through reverse migration. Cancer Prev Res (Phila). 2011 Jul; 4(7):962-72.
    View in: PubMed
    Score: 0.025
  15. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov. 2011 Jun; 1(1):44-53.
    View in: PubMed
    Score: 0.025
  16. The impact of phosphorylated AMP-activated protein kinase expression on lung cancer survival. Ann Oncol. 2012 Jan; 23(1):78-85.
    View in: PubMed
    Score: 0.024
  17. Gene expression profiling predicts the development of oral cancer. Cancer Prev Res (Phila). 2011 Feb; 4(2):218-29.
    View in: PubMed
    Score: 0.024
  18. DeltaNp63 overexpression, alone and in combination with other biomarkers, predicts the development of oral cancer in patients with leukoplakia. Clin Cancer Res. 2009 Oct 01; 15(19):6284-91.
    View in: PubMed
    Score: 0.022
  19. Identification of gene signatures and molecular markers for human lung cancer prognosis using an in vitro lung carcinogenesis system. Cancer Prev Res (Phila). 2009 Aug; 2(8):702-11.
    View in: PubMed
    Score: 0.022
  20. Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol. 2008 Jan 20; 26(3):354-60.
    View in: PubMed
    Score: 0.020
  21. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res. 2006 Jun 15; 12(12):3661-97.
    View in: PubMed
    Score: 0.018
  22. Expression of hepatoma-derived growth factor is a strong prognostic predictor for patients with early-stage non-small-cell lung cancer. J Clin Oncol. 2004 Aug 15; 22(16):3230-7.
    View in: PubMed
    Score: 0.015
  23. Gene expression screening of salivary gland neoplasms: molecular markers of potential histogenetic and clinical significance. J Mol Diagn. 2004 Aug; 6(3):180-90.
    View in: PubMed
    Score: 0.015
  24. Retinoic acid receptor beta and telomerase catalytic subunit expression in bronchial epithelium of heavy smokers. J Natl Cancer Inst. 2003 Jan 15; 95(2):165-8.
    View in: PubMed
    Score: 0.014
  25. Biologic correlates of a biochemoprevention trial in advanced upper aerodigestive tract premalignant lesions. Cancer Epidemiol Biomarkers Prev. 2002 Dec; 11(12):1605-10.
    View in: PubMed
    Score: 0.014
  26. Effects of N-(4-hydroxyphenyl)retinamide on hTERT expression in the bronchial epithelium of cigarette smokers. J Natl Cancer Inst. 2001 Aug 15; 93(16):1257-63.
    View in: PubMed
    Score: 0.013
  27. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res. 2001 Apr; 7(4):861-7.
    View in: PubMed
    Score: 0.012
  28. Retinoic acid receptor-beta as a prognostic indicator in stage I non-small-cell lung cancer. J Clin Oncol. 2000 Aug; 18(15):2798-804.
    View in: PubMed
    Score: 0.012
  29. Evaluation of tyrosinase mRNA as a tumor marker in the blood of melanoma patients. J Clin Oncol. 1997 Aug; 15(8):2826-31.
    View in: PubMed
    Score: 0.010
  30. Micronuclei, a biomarker for chemoprevention trials: results of a randomized study in oral pre-malignancy. Int J Cancer. 1994 Nov 15; 59(4):457-9.
    View in: PubMed
    Score: 0.008
  31. Elevated PDGFRB gene copy number gain is prognostic for improved survival outcomes in resected malignant pleural mesothelioma. Ann Diagn Pathol. 2014 Jun; 18(3):140-5.
    View in: PubMed
    Score: 0.007
  32. Prognostic implications of tumoral expression of insulin like growth factors 1 and 2 in patients with non-small-cell lung cancer. Clin Lung Cancer. 2014 May; 15(3):213-21.
    View in: PubMed
    Score: 0.007
  33. Prediction of survival in resected non-small cell lung cancer using a protein expression-based risk model: implications for personalized chemoprevention and therapy. Clin Cancer Res. 2014 Apr 01; 20(7):1946-54.
    View in: PubMed
    Score: 0.007
  34. Elevated cyclin D1 expression is predictive for a benefit from TPF induction chemotherapy in oral squamous cell carcinoma patients with advanced nodal disease. Mol Cancer Ther. 2013 Jun; 12(6):1112-21.
    View in: PubMed
    Score: 0.007
  35. DNA repair biomarker profiling of head and neck cancer: Ku80 expression predicts locoregional failure and death following radiotherapy. Clin Cancer Res. 2011 Apr 01; 17(7):2035-43.
    View in: PubMed
    Score: 0.006
  36. Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer. Cancer Prev Res (Phila). 2010 Jul; 3(7):800-9.
    View in: PubMed
    Score: 0.006
  37. Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer. Mol Cancer Ther. 2010 Jun; 9(6):1755-63.
    View in: PubMed
    Score: 0.006
  38. Expression of interleukin-1 receptor-associated kinase-1 in non-small cell lung carcinoma and preneoplastic lesions. Clin Cancer Res. 2010 Jan 01; 16(1):34-44.
    View in: PubMed
    Score: 0.006
  39. Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst. 2009 May 20; 101(10):708-20.
    View in: PubMed
    Score: 0.005
  40. Cyclin D1 and cancer development in laryngeal premalignancy patients. Cancer Prev Res (Phila). 2009 Jan; 2(1):14-21.
    View in: PubMed
    Score: 0.005
  41. Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. Cancer. 2006 Aug 01; 107(3):563-9.
    View in: PubMed
    Score: 0.004
  42. Tetranucleotide microsatellite instability in surgical margins for prediction of local recurrence of head and neck squamous cell carcinoma. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 1):4022-8.
    View in: PubMed
    Score: 0.004
  43. Aberrant promoter methylation of multiple genes in bronchial brush samples from former cigarette smokers. Cancer Res. 2002 Jan 15; 62(2):351-5.
    View in: PubMed
    Score: 0.003
  44. Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations. Urology. 2001 Apr; 57(4 Suppl 1):4-27.
    View in: PubMed
    Score: 0.003
  45. Expression of vascular endothelial growth factor and microvessel density in head and neck tumorigenesis. Clin Cancer Res. 2000 Jul; 6(7):2821-8.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.